Libé R, Huillard O. Adrenocortical carcinoma: diagnosis, prognostic classification and treatment of localized and advanced disease. Cancer Treat Res Commun. 2023;37:100759.

Google Scholar 

Else T, Williams AR, Sabolch A, Jolly S, Miller BS, Hammer GD. Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. J Clin Endocrinol Metabolism. 2014;99:455–61.

Article  CAS  Google Scholar 

Mete O, Erickson LA, Juhlin CC, De Krijger RR, Sasano H, Volante M, et al. Overview of the 2022 WHO classification of adrenal cortical tumors. Endocr Pathol. 2022;33:155–96.

Article  CAS  Google Scholar 

Libé R, Borget I, Ronchi CL, Zaggia B, Kroiss M, Kerkhofs T, et al. Prognostic factors in stage III–IV adrenocortical carcinomas (ACC): an European network for the study of adrenal tumor (ENSAT) study. Ann Oncol. 2015;26:2119–25.

Article  Google Scholar 

Berruti A, Fassnacht M, Haak H, Else T, Baudin E, Sperone P, et al. Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer. Eur Urol. 2014;65:832–8.

Article  CAS  Google Scholar 

Abiven G, Coste J, Groussin L, Anract P, Tissier F, Legmann P, et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of Cortisol-Secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metabolism. 2006;91:2650–5.

Article  CAS  Google Scholar 

Puglisi S, Calabrese A, Ferraù F, Violi MA, Laganà M, Grisanti S, et al. New findings on presentation and outcome of patients with adrenocortical cancer: results from a National cohort study. J Clin Endocrinol Metabolism. 2023;108:2517–25.

Article  CAS  Google Scholar 

Puglisi S, Perotti P, Pia A, Reimondo G, Terzolo M. Adrenocortical carcinoma with hypercortisolism. Endocrinol Metab Clin North Am. 2018;47:395–407.

Article  Google Scholar 

Seccia TM, Fassina A, Nussdorfer GG, Pessina AC, Rossi GP. Aldosterone-producing adrenocortical carcinoma: an unusual cause of conn’s syndrome with an ominous clinical course. Endocr Relat Cancer. 2005;12:149–59.

Article  Google Scholar 

Ayala-Ramirez M, Jasim S, Feng L, Ejaz S, Deniz F, Busaidy N, et al. Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol. 2013;169:891–9.

Article  CAS  Google Scholar 

Braun LT, Vogel F, Reincke M. Long-term morbidity and mortality in patients with Cushing’s syndrome. J Neuroendocrinology [Internet]. 2022 [cited 2023 Feb 22];34. Available from: https://onlinelibrary.wiley.com/doi/https://doi.org/10.1111/jne.13113

Tabarin A, Haissaguerre M, Lassole H, Jannin A, Paepegaey A-C, Chabre O, et al. Efficacy and tolerance of Osilodrostat in patients with cushing’s syndrome due to adrenocortical carcinomas. Eur J Endocrinol. 2022;186:K1–4.

Article  CAS  Google Scholar 

Tőke J, Uhlyarik A, Lohinszky J, Stark J, Huszty G, Micsik T, et al. Prognostic factors and mitotane treatment of adrenocortical cancer. Two decades of experience from an institutional case series. Front Endocrinol. 2022;13:952418.

Article  Google Scholar 

Fassnacht M, Dekkers OM, Else T, Baudin E, Berruti A, De Krijger RR, et al. European society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European network for the study of adrenal tumors. Eur J Endocrinol. 2018;179:G1–46.

Article  CAS  Google Scholar 

Fassnacht M, Puglisi S, Kimpel O, Terzolo M. Adrenocortical carcinoma: a practical guide for clinicians. Lancet Diabetes Endocrinol. 2025;13:438–52.

Article  CAS  Google Scholar 

Bledsoe T, Island DP, Ney RL, Liddle GW. An effect of o,p′-DDD on the Extra-adrenal metabolism of cortisol in man. J Clin Endocrinol Metabolism. 1964;24:1303–11.

Article  CAS  Google Scholar 

Carrozza C, Lapolla R, Gervasoni J, Rota CA, Locantore P, Pontecorvi A, et al. Assessment of salivary free cortisol levels by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in patients treated with mitotane. HJ. 2012;11:344–9.

Article  Google Scholar 

Marques JVO, Boguszewski CL. Medical therapy in severe hypercortisolism. Best Pract Res Clin Endocrinol Metab. 2021;35:101487.

Article  CAS  Google Scholar 

Ceccato F, Barbot M, Zilio M, Frigo AC, Albiger N, Camozzi V, et al. Screening tests for cushing’s syndrome: urinary free cortisol role measured by LC-MS/MS. J Clin Endocrinol Metabolism. 2015;100:3856–61.

Article  CAS  Google Scholar 

Kamenický P, Droumaguet C, Salenave S, Blanchard A, Jublanc C, Gautier J-F, et al. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-Dependent cushing’s syndrome. J Clin Endocrinol Metabolism. 2011;96:2796–804.

Article  Google Scholar 

Paragliola RM, Torino F, Papi G, Locantore P, Pontecorvi A. Role of mitotane in adrenocortical Carcinoma – Review and state of the Art. Eur Endocrinol. 2018;14:62.

Google Scholar 

Hescot S, Slama A, Lombès A, Paci A, Remy H, Leboulleux S, et al. Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells. Endocrine-related Cancer. 2013;20:371–81.

Article  CAS  Google Scholar 

Ollivier M, Haissaguerre M, Ferriere A, Tabarin A. Should we avoid using ketoconazole in patients with severe cushing’s syndrome and increased levels of liver enzymes? Eur J Endocrinol. 2018;179:L1–2.

Article  CAS  Google Scholar 

Kroiss M, Quinkler M, Lutz WK, Allolio B, Fassnacht M. Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma: CYP3A4 induction by mitotane. Clin Endocrinol. 2011;75:585–91.

Article  CAS  Google Scholar 

Corcuff J-B, Young J, Masquefa-Giraud P, Chanson P, Baudin E, Tabarin A. Rapid control of severe neoplastic hypercortisolism with Metyrapone and ketoconazole. Eur J Endocrinol. 2015;172:473–81.

Article  CAS  Google Scholar 

Daniel E, Aylwin S, Mustafa O, Ball S, Munir A, Boelaert K, et al. Effectiveness of Metyrapone in treating cushing’s syndrome: A retrospective multicenter study in 195 patients. J Clin Endocrinol Metabolism. 2015;100:4146–54.

Article  CAS  Google Scholar 

Claps M, Cerri S, Grisanti S, Lazzari B, Ferrari V, Roca E, et al. Adding Metyrapone to chemotherapy plus mitotane for cushing’s syndrome due to advanced adrenocortical carcinoma. Endocrine. 2018;61:169–72.

Article  CAS  Google Scholar 

Haissaguerre M, Puerto M, Nunes M-L, Tabarin A. Efficacy and tolerance of Osilodrostat in patients with severe cushing’s syndrome due to non-pituitary cancers. Eur J Endocrinol. 2020;183:L7–9.

Article  CAS  Google Scholar 

Constantinescu SM, Driessens N, Lefebvre A, Furnica RM, Corvilain B, Maiter D. Etomidate infusion at low doses is an effective and safe treatment for severe cushing’s syndrome outside intensive care. Eur J Endocrinol. 2020;183:161–7.

Article  CAS  Google Scholar 

Wan Muhamad Hatta SF, Daly R, Chacko C, Raghavan R. A case of etomidate use in management of adrenocortical carcinoma with hypercortisolemia. J Endocrinol Metab. 2020;10:190–4.

Article  Google Scholar 

Łebek-Szatańska A, Nowak KM, Zgliczyński W, Baum E, Żyłka A, Papierska L. Low-dose etomidate for the management of severe hypercortisolaemia in different clinical scenarios: a case series and review of the literature. Therapeutic Adv Endocrinol. 2019;10:204201881982554.

Article  Google Scholar 

Kwon A, Choi Y, Jung JW, Suh J, Kim H-S. Using etomidate in a Two-month-old infant with Cushing syndrome due to adrenocortical carcinoma. Jcrpe. 2022;14:102–6.

Article  Google Scholar 

Hahner S, Stürmer A, Fassnacht M, Hartmann RW, Schewe K, Cochran S, et al. Etomidate unmasks intraadrenal regulation of steroidogenesis and proliferation in adrenal cortical cell lines. Horm Metab Res. 2010;42:528–34.

Article  CAS  Google Scholar 

Castinetti F, Nieman LK, Reincke M, Newell-Price J. Approach to the patient treated with steroidogenesis inhibitors. J Clin Endocrinol Metabolism. 2021;106:2114–23.

Article  Google Scholar 

Dzialach L, Sobolewska J, Respondek W, Wojciechowska-Luzniak A, Kuca P, Witek P. Is there still a place for etomidate in the management of Cushing’s syndrome? The experience of a single center of low-dose etomidate and combined etomidate-osilodrostat treatment in severe hypercortisolemia. Endocrine [Internet]. 2024 [cited 2025 Jan 31]; Available from: https://link.springer.com/https://doi.org/10.1007/s12020-024-04135-1

Mah PM, Jenkins RC, Rostami-Hodjegan A, Newell‐Price J, Doane A, Ibbotson V, et al. Weight‐related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clin Endocrinol. 2004;61:367–75.

Article  CAS  Google Scholar 

Störmann S, Schopohl J. New and emerging drug therapies for cushing’s disease. Expert Opin Pharmacother. 2018;19:1187–200.

Article  Google Scholar 

Chortis V, Taylor AE, Schneider P, Tomlinson JW, Hughes BA, O’Neil DM, et al. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-Reductase, explaining the need for personalized glucocorticoid and androgen replacement. J Clin Endocrinol Metabolism. 2013;98:161–71.

Article  CAS  Google Scholar 

Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR, et al. Consensus on diagnosis and management of cushing’s disease: a guideline update. Lancet Diabetes Endocrinol. 2021;9:847–75.

Article  Google Scholar